Immunomodulatory therapies delay disease progression in multiple sclerosis

Multiple Sclerosis

Volumn 22, Issue 13, 2016, Pages 1732-1740

  Bergamaschi, Roberto ^a   Quaglini, Silvana ^b   Tavazzi, Eleonora ^a   Amato, Maria Pia ^c   Paolicelli, Damiano ^d   Zipoli, Valentina ^c   Romani, Alfredo ^a   Tortorella, Carla ^d   Portaccio, Emilio ^c   D'Onghia, Mariangela ^d   Garberi, Francesca ^b   Bargiggia, Valeria ^a   Trojano, Maria ^d  

^a UNIVERSITY OF PAVIA   (Italy)

^b C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d UNIVERSITY OF BARI   (Italy)

Author keywords

Bayesian analysis; clinical research methods; disease progression; immune therapies; Multiple sclerosis; prognosis

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; CYCLOPHOSPHAMIDE; GLATIRAMER; IMMUNOGLOBULIN; INTERFERON BETA SERINE; METHOTREXATE; MITOXANTRONE; NATALIZUMAB;

ADULT; ARTICLE; BAYES THEOREM; BAYESIAN RISK ESTIMATE FOR MULTIPLE SCLEROSIS; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; IMMUNOTHERAPY; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE ASSESSMENT; NEUROLOGIC EXAMINATION; OBSERVATIONAL STUDY; RISK REDUCTION; TREATMENT OUTCOME; TREATMENT RESPONSE; DISEASE EXACERBATION; MIDDLE AGED; OUTCOME ASSESSMENT; PROCEDURES; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

ADULT; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 84994634473     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512445941     Document Type: Article

References (35)

1. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: A randomised study. Lancet 2001; 357: 1576-1582.
2. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): A randomised, double-blind, placebo-controlled trial. Lancet 2009; 374: 1503-1511.
3. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000; 343: 898-904.
4. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67: 1242-1249.
5. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285-294.
6. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998; 352: 1498-1504.
7. IFNB Multiple Sclerosis Study Group. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 2001; 57: S3-S9. [. Classical article 1993.]
8. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 2001; 57: S16-S24. [ 1995 ]
9. Brown MG, Kirby S, Skedgel C, et al. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? Neurology 2007; 69: 1498-1507.
10. Rudick RA, Cutter GR, Baier M, et al. Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients. Mult Scler 2005; 11: 626-634.
11. Trojano M, Pellegrini F, Fuiani A, et al. New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol 2007; 61: 300-306.
12. Trojano M, Pellegrini F, Paolicelli D, et al. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. Ann Neurol 2009; 66: 513-520.
13. Ebers GC, Heigenhauser L, Daumer M, et al. Disability as an outcome in MS clinical trials. Neurology 2008; 71: 624-631.
14. Bergamaschi R, Berzuini C, Romani A, et al. Predicting secondary progression in relapsing-remitting multiple sclerosis: A Bayesian analysis. J Neurol Sci 2001; 189: 13-21.
15. Bergamaschi R, Quaglini S, Trojano M, et al. Early prediction of the long term evolution of multiple sclerosis: The Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score. J Neurol Neurosurg Psychiatry 2007; 78: 757-759.
16. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983; 13: 227-231.
17. Kremenchutzky M, Cottrell D, Rice G, et al. The natural history of multiple sclerosis: A geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: A re-evaluation. Brain 1999; 122: 1941-1950.
18. Theobald K, Capan M, Herbold M, et al. Quality assurance in non-interventional studies. Ger Med Sci 2009; 7: Doc29.
19. Goodin DS, Bates D,. Treatment of early multiple sclerosis: The value of treatment initiation after a first clinical episode. Mult Scler 2009; 15: 1175-1182.
20. Ford CC, Johnson KP, Lisak RP, et al. A prospective open-label study of glatiramer acetate: Over a decade of continuous use in multiple sclerosis patients. Mult Scler 2006; 12: 309-320.
21. Ebers GC, Traboulsee A, Li D, et al. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry 2010; 81: 907-912.
22. Kinkel RP, Kollman C, O'Connor P, et al. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 2006; 66: 678-684.
23. Milanese C, La Mantia L, Palumbo R, et al. A post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: Different response in drop-outs and treated patients. J Neurol Neurosurg Psychiatry 2003; 74: 1689-1692.
24. Baumhackl U,. The search for a balance between short and long-term treatment outcomes in multiple sclerosis. J Neurol 2008; 255 (Suppl. 1): 75-83.
25. Raftery J,. Multiple sclerosis risk sharing scheme: A costly failure. BMJ 2010; 340: c1672.
26. Trojano M,. Is it time to use observational data to estimate treatment effectiveness in multiple sclerosis? Neurology 2007; 69: 1478-1479.
27. Bergamaschi R,. Prognosis of multiple sclerosis: Clinical factors predicting the late evolution for an early treatment decision. Expert Rev Neurother 2006; 6: 357-364.
28. Spiegelhalter DJ, Myles JP, Jones DR, et al. Methods in health service research. An introduction to Bayesian methods in health technology assessment. BMJ 1999; 319: 508-512.
29. Lilford RJ, Braunholtz D,. The statistical basis of public policy: A paradigm shift is overdue. BMJ 1996; 313: 603-607.
30. Berzuini C, Larizza C,. A unified approach for modelling longitudinal and failure time data, with application in medical monitoring. IEEE Trans Patt Anal Machine Intell 1996; 2: 109-110-123.
31. Tremlett H, Yinshan Z, Devonshire V,. Natural history of secondary-progressive multiple sclerosis. Mult Scler 2008; 14: 314-324.
32. Langer-Gould A, Popat RA, Huang SM, et al. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: A systematic review. Arch Neurol 2006; 63: 1686-1691.
33. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
34. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911-923.
35. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006; 355: 1124-1140.